2-[(E)-[4-[(4-bromo-2,3,5,6-tetramethylphenyl)methoxy]-3-methoxyphenyl]methylideneamino]guanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[(E)-[4-[(4-bromo-2,3,5,6-tetramethylphenyl)methoxy]-3-methoxyphenyl]methylideneamino]guanidine
• 化学式: C₂₀H₂₅BrN₄O₂
• 分子量: 433.3
• InChiKey: ZRSVMHWJINSKDZ-PGGKNCGUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• EP1751553B1
  申请人：——

  公开号：EP1751553B1

  公开（公告）日：2008-10-08
• IDENTIFICATION OF ANTI-PRION DRUGS BY HIGH-THROUGHPUT SCREENING BASED ON SIFT
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP1751553A2

  公开（公告）日：2007-02-14
• Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift)
  申请人：Bertsch Uwe

  公开号：US20100029773A1

  公开（公告）日：2010-02-04

  The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.
• [EN] SYSTEMATIC IDENTIFICATION OF NEW ANTI-PRION DRUGS BY HIGH-THROUGHPUT SCREENING BASED ON SCANNING FOR INTENSELY FLUORESCENT TARGETS (SIFT)<br/>[FR] IDENTIFICATION SYSTEMATIQUE DE NOUVEAUX MEDICAMENTS ANTI-PRIONS PAR CRIBLAGE A HAUT RENDEMENT FONDE SUR UN BALAYAGE DE CIBLES INTENSEMENT FLUORESCENTES (SIFT)
  申请人：UNIV MUENCHEN L MAXIMILIANS

  公开号：WO2005116640A2

  公开（公告）日：2005-12-08

  The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.